Phase I study of single-agent CC-292, a highly selective bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

Jennifer R. Brown, Wael A. Harb, Brian T. Hill, Janice Gabrilove, Jeff P. Sharman, Marshall T. Schreeder, Paul M. Barr, James M. Foran, Thomas P. Miller, Jan A. Burger, Kevin R. Kelly, Daruka Mahadevan, Shuo Ma, Yan Li, Daniel W. Pierce, Evelyn Barnett, Jeffrey Marine, Monika Miranda, Ada Azaryan, Xujie YuPilar Nava-Parada, Jay Mei, Thomas J. Kipps

Research output: Contribution to journal › Letter › peer-review

34 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I study of single-agent CC-292, a highly selective bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia'. Together they form a unique fingerprint.